Omar Ford
Omar Ford is MD+DI's managing editor. You can reach him at [email protected].
CardioFocus Finishes up Enrollment for HeartLight X3 Trial
The Marlborough, MA-based company said it could pick up a CE mark for the endoscopic ablation system sometime in mid-2019.
Investigators on the Path to Alzheimer’s Detection Test
A team from Brigham and Women’s Hospital are developing a test that can detect tau protein, a calling card for Alzheimer’s disease.
Tiny Wearable Device Warns of Exposure to UV Light
The technology was designed by Northwestern Medicine along with Northwestern’s McCormick School of Engineering scientists and has the potential to monitor, separately and accurately, UVB and UVA exposure for people at high risk for melanoma.
GRAIL’s SUMMIT Will Help Define its Liquid Biopsy Path
The Menlo Park, CA-based company’s 50,000-patient trial will launch in 2019 and could be one of the most significant events of the year for the liquid biopsy market.
Are Smaller Hip Implants in Older Patients More Cost Effective?
University of Bristol Medical School Researchers led a study that shows cemented metal-on-plastic hip replacements less than 36 mm in diameter are the most cost-effective in patients older than 65.
Is 2019 Going to Be a Standout Year for TAVR?
JenaValve has received a nod from FDA to expand enrollment in an IDE of its TAVR system. The measure comes at a time when the TAVR landscape is expected to shift.
Diabeloop Is 2nd to Win CE Mark for Artificial Pancreas System
The small startup will now be able to compete against Medtronic’s MiniMed 670g, but there are other technologies still in development that could have an even greater impact on the market.
Auris Scores Big with $200M Raise for Robotics Platform
The Redwood City, CA-based company’s financing raise is the perfect example of the strength and support the robotics market now commands in healthcare.
7 Key Moments for the Digital Health Space in 2018
Here are seven key moments in the digital health space that helped moved the space forward in 2018.
Another EpiPen Is Now on the Market
Teva Pharmaceuticals received approval for a generic version of Mylan’s EpiPen back in August, which came on the heels of a shortage of the emergency allergy shot. The generic gives another option to users.
Medtronic Eyes Familiar Face in New Acquisition
The Dublin-based company will pick up Nutrino, a frequent collaborator and a company that uses artificial intelligence for nutrition-related services.
Looking at the AI Renaissance in Medtech
Right now we’re in the middle of the Artificial Intelligence Renaissance for medtech. But what does this mean for companies? Is this a fad or is AI here to stay in medtech. MD+DI Managing Editor Omar Ford gives his thoughts on this emerging trend.
7 Things That Have Medtech Companies Thankful in 2018
Here are seven reasons medtech companies have to be thankful in 2018.
Using AI to Enhance Kidney Disease Detection
RenalytixAI has raised $29 million to help advance tests for early detection of kidney disease and a test that will help in the accurate management of kidney transplant rejection.
Boston Sci Puts up $4B for BTG
The Marlborough, MA-based company hasn’t been shy about building up its portfolio through M&A, the only question now is can it slip in another deal before the end of the year.